Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/05/2022* -- Results Q2 2022 -- 0.11 --
08/05/2022* 17:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 0.11 0.11 2.33%
05/05/2022 17:00 EST Earnings Call Q1 2022 -- -- --
03/01/2022 -- Results Q4 2021 0.01 0.09 -88.29%
03/01/2022 17:00 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 0.07 0.06 24.56%
11/09/2021 17:00 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/05/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/05/2022
Beat/Miss Upgrade
Return Since 20.60%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States.
URL https://www.certara.com
Investor Relations URL https://ir.certara.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Health Information Services
Equity Style Small Cap/Growth
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release May. 05, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
-15.72%
-20.69%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
9.38%
18.11%
-22.34%
-12.39%
-4.17%
-4.35%
-11.77%
-18.44%
-82.87%
147.4%
-29.78%
149.9%
74.07%
278.8%
-89.82%
-77.58%
19.36%
21.06%
99.11%
5.36%
75.47%
-34.86%
-1.83%
-5.73%
--
--
--
--
--
--
-18.99%
-78.70%
As of June 24, 2022.

Profile

Edit
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States.
URL https://www.certara.com
Investor Relations URL https://ir.certara.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Health Information Services
Equity Style Small Cap/Growth
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release May. 05, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
BFTR 174589.0 USD 2.50%
F00000J3NK 688543.0 USD 1.60%
MNDGX 34.79M USD 1.42%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CERT Tweets